Transcription factor 21 gene polymorphism in patients with coronary artery disease
Authors Hamed WA, Hammouda GE, El-Hefnawy SM, Abd El-Gayed EM
Received 5 September 2016
Accepted for publication 22 November 2016
Published 14 February 2017 Volume 2017:8 Pages 13—18
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Richard Kones
Waleed Abdou Hamed,1 Ghada E Hammouda,2 Sally M El-Hefnawy,2 Eman M Abd El-Gayed2
1Cardiology Department, 2Biochemistry Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt
Background: CAD is the most common type of heart disease and the leading cause of death in both men and women. Transcription factor 21 (TCF21) is required for normal epicardial development and regulates epicardium-derived cell (EPDC) differentiation into smooth muscle and fibroblast lineages.
Objectives: The aim of this study was to investigate the distribution of TCF21 (12190287G/C) gene polymorphism in patients with CAD and its association with other clinical and laboratory variables in these patients.
Patients and methods: This study was carried out in 100 patients with CAD, and 50 healthy subjects served as controls. All studied subjects underwent laboratory investigations, including measurement of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), creatinine kinase-MB (CK-MB), troponin I (TnI) and genotyping of TCF21 (12190287G/C) gene using the TaqMan Allelic Discrimination assay technique.
Results: Serum creatinine, TC, TG, LDL-c, CK-MB and TnI were significantly higher in patients with CAD than in the control group. There was a statistically significant difference regarding genotype frequency of TCF21 (12190287G/C) polymorphism between the two studied groups, with the highest frequency of GG genotype among the control group, while CC genotype had the highest frequency in the patient group. C allele was more frequent in the patient group, while G allele was more frequent in the control group.
Conclusion: CC genotype and C allele of TCF21 (12190287G/C) polymorphism are considered as genetic risk factors for CAD; these findings could have an impact on the future preventive and management protocols in this group of patients.
Keywords: coronary artery disease, transcription factor, gene polymorphism
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]